Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cipla
Dow
US Department of Justice
Healthtrust
Express Scripts
Deloitte
Merck
QuintilesIMS

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MESALAMINE

« Back to Dashboard

Clinical Trials for Mesalamine

Trial ID Title Status Sponsor Phase Summary
NCT00063414 ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis Completed Ionis Pharmaceuticals, Inc. Phase 2 This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.
NCT00098111 Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease Terminated Massachusetts General Hospital Phase 3 The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00109473 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Genentech, Inc. Phase 2 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00109473 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Children's Hospital Medical Center, Cincinnati Phase 2 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00194818 Asacol Dosing Study for Active Ulcerative Colitis Completed Procter and Gamble Phase 4 We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.
NCT00194818 Asacol Dosing Study for Active Ulcerative Colitis Completed University of Washington Phase 4 We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Mesalamine

Condition Name

Condition Name for Mesalamine
Intervention Trials
Ulcerative Colitis 35
Healthy 9
Crohn's Disease 5
Inflammatory Bowel Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mesalamine
Intervention Trials
Colitis, Ulcerative 41
Colitis 41
Ulcer 40
Crohn Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mesalamine

Trials by Country

Trials by Country for Mesalamine
Location Trials
United States 376
Canada 27
India 25
Poland 18
Italy 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mesalamine
Location Trials
Florida 20
California 19
Texas 18
Michigan 15
Maryland 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mesalamine

Clinical Trial Phase

Clinical Trial Phase for Mesalamine
Clinical Trial Phase Trials
Phase 4 11
Phase 3 24
Phase 2/Phase 3 3
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mesalamine
Clinical Trial Phase Trials
Completed 41
Recruiting 14
Terminated 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mesalamine

Sponsor Name

Sponsor Name for Mesalamine
Sponsor Trials
Shire 9
Valeant Pharmaceuticals International, Inc. 8
Ferring Pharmaceuticals 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mesalamine
Sponsor Trials
Industry 56
Other 49
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Daiichi Sankyo
Cerilliant
Chinese Patent Office
US Department of Justice
Queensland Health
Fuji
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.